NFKB1 and COVID-19: The identified biomarkers CLEC12A and ACHE might both examine the ability of an individual to inhibit upstream activation of the NF-κB pathway, albeit by different mechanisms, and thus the ability to prevent an overwhelming immune response in COVID-19.